Microsoft strongly encourages users to switch to a different browser than Internet Explorer as it no longer meets modern web and security standards. Therefore we cannot guarantee that our site fully works in Internet Explorer. You can use Chrome or Firefox instead.

Will Adagio's COVID Antibody Therapy Be Too Late to the Party?

TheMotleyFool

0 0

Will Adagio's COVID Antibody Therapy Be Too Late to the Party?

Adagio Therapeutics (NASDAQ: ADGI) plans to file for Emergency Use Authorization (EUA) with the U.S. Food and Drug Administration for its COVID-19 antibody therapy in the second quarter of 2022. In this Motley Fool Live video recorded on Nov. 16, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss whether or not Adagio might be too late to the party with this regulatory filing.

Source Fool.com

Like: 0

ADGI

Share